Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem‐cell transplantation is a prognostic marker of longer progression‐free survival and overall survival-Reference-Cited by-同舟云学术

Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem‐cell transplantation is a prognostic marker of longer progression‐free survival and overall survival

Published:2022-04-05 Issue:2 Volume:198 Page:278-287
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Dávila Julio¹^ORCID,González‐Calle Verónica²,Escalante Fernando³,Cerdá Seila⁴,Puig Noemí²,García‐Sanz Ramón²^ORCID,Bárez Abelardo¹,Montes Carmen⁵,López Rosa⁶,Alonso José María⁷,Aguilar Carlos⁸,García‐Mateo Aránzazu⁹,Labrador Jorge¹⁰,Aguilera Carmen¹¹,García‐Coca Alfonso¹²,Hernández Roberto¹³,Mateos María‐Victoria²^ORCID,Ocio Enrique M.⁵^ORCID

Affiliation:

1. Department of Hematology Complejo Asistencial de Avila Spain

2. Department of Hematology University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research‐IBMCC (USAL‐CSIC) Salamanca Spain

3. Department of Hematology Complejo Asistencial Universitario de León León Spain

4. Department of Hematology Hospital de Laredo Laredo Spain

5. Department of Hematology Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria Santander Spain

6. Department of Hematology Hospital Virgen del Puerto Plasencia Spain

7. Department of Hematology Complejo Asistencial Universitario de Palencia Palencia Spain

8. Department of Hematology Complejo Asistencial de Soria Soria Spain

9. Department of Hematology Complejo Asistencial de Segovia Segovia Spain

10. Department of Hematology Complejo Asistencial Universitario de Burgos Burgos Spain

11. Department of Hematology Hospital El Bierzo, Ponferrada Spain

12. Department of Hematology Hospital Clínico Universitario de Valladolid Valladolid Spain

13. Department of Hematology Complejo Asistencial de Zamora Zamora Spain

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18182

Reference39 articles.

1. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

3. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

4. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

5. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunoparesis Recovery in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients, an Independent Prognostic Factor That Complements Minimal Residual Disease;2024-09-02

2. Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis;Clinical Lymphoma Myeloma and Leukemia;2024-07

3. Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis;Hematology;2024-03-12

4. Development of a nomogram prognostic model for early Grade ≥ 3 infection in newly diagnosed multiple myeloma based on immunoparesis;International Immunopharmacology;2024-01

5. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection;Haematologica;2023-11-30